Celltrion Pharm, Inc. (KOSDAQ:068760)

Market Cap	2.44T +4.9%
Revenue (ttm)	274.73B +53.2%
Net Income	26.03B +146.8%
EPS	583.36 +146.0%
Shares Out	43.50M
PE Ratio	96.00
Forward PE	n/a
Dividend	200.00 (0.37%)
Ex-Dividend Date	Dec 29, 2025

Volume	48,133
Average Volume	69,157
Open	56,300
Previous Close	55,700
Day's Range	55,900 - 56,500
52-Week Range	43,627 - 78,300
Beta	1.18
RSI	41.46
Earnings Date	n/a

About Celltrion Pharm

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea. Celltrion Pharm, Inc. (KOSDAQ:A068760) operat...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1976
• Employees: 328
• Stock Exchange: KOSDAQ
• Ticker Symbol: 068760

Financial Performance

In 2020, Celltrion Pharm's revenue was 233.57 billion, an increase of 34.61% compared to the previous year's 173.51 billion. Earnings were 20.94 billion, an increase of 143.42%.